BHFS Medical & Wellness

Call Directions Website

BHFS Medical & Wellness To schedule a session, please contact the clinic at 866-943-7779 or send an email to [email protected].

Founded in 2007, BHFS Medical & Wellness in Flower Mound and Burleson, Texas, is dedicated to providing compassionate, comprehensive medical and wellness services that support individuals through every stage of life. We specialize in:
*Family Medical Services
*Women's Health Services
*Psychiatric & Counseling Services
*Suboxone & Addiction Services
*IOP services for children and adults
*Private Pediatric PHP Program with Educational Services

We also offer special programs for the uninsured, low-income, and medically underserved persons.

"GLP-1s eat your muscle" is the line you'll hear all week. New evidence says the story is more useful than that.THE OBSE...
11/13/2026

"GLP-1s eat your muscle" is the line you'll hear all week. New evidence says the story is more useful than that.

THE OBSERVATION IS REAL. THE CAUSE ISN'T WHAT FEEDS SAY.
Body-composition scans show lean mass can fall during weight loss on incretin therapy. That observation is real. But a new laboratory study found human muscle cells exposed to these medicines showed no meaningful atrophy, mitochondrial damage, or disruption to muscle-fibre formation. The converging explanation: lean loss tracks the caloric deficit and reduced mechanical loading, not the medicine attacking muscle.

THE 40-WEEK TRIAL
Adults aged 50 to 70 on a weight-loss medicine were assigned to usual activity or supervised resistance training three times a week for 40 weeks. Both groups lost similar weight. The training group lost less measured lean tissue and gained strength. Strength declined in the medication-only group. Structured training made a meaningful difference while weight loss continued.

WHAT TO ASK YOUR CARE TEAM
Resistance activity you can sustain, built gradually. Protein needs: a range of about 1.2 to 1.6 grams per kilogram per day is often discussed during weight loss, calculated for your circumstances under guidance. Track more than weight: strength, function, nutrition, and body-composition trends.

NOT JUST SMALLER. STRONGER.
The future of weight management is not only about becoming smaller. It is about building a healthier, stronger body as you move forward.

Read the full evidence review on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician. Dr. Allen is a Functional Medicine Consultant & Medical Researcher, not a physician. Dr. Sullivan Bryant, DO, is the supervising physician of record.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

The peptide everyone is talking about was approved, then withdrawn. The history explains everything.THE TIMELINE1990: an...
11/12/2026

The peptide everyone is talking about was approved, then withdrawn. The history explains everything.

THE TIMELINE
1990: an FDA-approved diagnostic product. 1997: an FDA-approved pediatric product. 2008: the maker discontinues both and requests withdrawal. 2009: the withdrawals take effect. 2013: FDA determines the products were not withdrawn for safety or effectiveness reasons. A business decision.

WHY THE HISTORY MATTERS NOW
A past approval belongs to specific products and their approved indications. It does not transfer to every preparation or use of the same ingredient today. A compounding category listing is not FDA approval either. Approval status is business history. Quality depends on the pharmacy, the documentation, and the supervision.

THE VERIFIABLE FLOOR
Testing: purity, identity, sterility, endotoxin, content. The quality questions you can verify in writing. But testing does not turn a compounded preparation into an approved drug, prove effectiveness, or guarantee a result.

HISTORY IS A FILTER, NOT A SHORTCUT
Ask what the product's current status is. Ask who prepares and oversees it. Ask what quality information you can review.

Read the full history on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician. Dr. Allen is a Functional Medicine Consultant & Medical Researcher, not a physician. Dr. Sullivan Bryant, DO, is the supervising physician of record.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

The biggest telehealth company in America just put a launch date on peptides. Here's the honest read.THE LAUNCHLate Nove...
11/11/2026

The biggest telehealth company in America just put a launch date on peptides. Here's the honest read.

THE LAUNCH
Late November: a clinician-led peptide offering starting with sermorelin, glutathione, NAD+ and B12, with blood testing. Two recovery peptides are named for later, when the regulatory environment permits. That is not an approval, and it is not imminent. The quarter itself was mixed: strong revenue growth alongside a surprise loss and a reduced outlook.

WHAT IT IS NOT
A company launch is not a clinical endorsement. The two later peptides are not approved and not part of the announced launch. Compounded products are not FDA-reviewed for safety, effectiveness or quality before marketing. The federal comment window closes November 13, and rulemaking continues after that.

WHY IT MATTERS IN BURLESON
Mainstream attention brings better questions, not better shortcuts. Ask what is being offered, what is established, what remains uncertain, and who monitors your care. The clinic worth trusting pairs access with labs, testing, supervision, and honest conversations about what is known.

Name your goal. Ask about evidence and status. Understand the care plan.

Read the full analysis on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician. Dr. Allen is a Functional Medicine Consultant & Medical Researcher, not a physician. Dr. Sullivan Bryant, DO, is the supervising physician of record.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

A federal policy changed this week. Here's what it actually says versus what the headlines claim.WHAT THE POLICY ACTUALL...
11/09/2026

A federal policy changed this week. Here's what it actually says versus what the headlines claim.

WHAT THE POLICY ACTUALLY SAYS
HHS issued an interim enforcement-discretion policy covering BPC-157 acetate and five other peptides through qualifying 503A pharmacies. It applies only if strict conditions are met: patient-specific prescription, documented sourcing with a certificate of analysis, adverse-event reporting, and single-ingredient products.

WHAT THE HEADLINES CLAIM
That BPC-157 is now legal. That it is FDA-approved. That the bulks list has been updated. That every seller qualifies. That an advisory vote proved it works. None of that is in the policy.

THE DISTINCTION THAT MATTERS
Enforcement discretion is an agency's stated approach to enforcement. It is conditional, non-binding, and revisitable. It is not legalization, and it is not FDA approval. Compounded drugs receive no pre-sale FDA check of safety, effectiveness or quality, and rulemaking on the bulks list continues.

If you're considering peptide care: ask what exactly is being proposed, request the documentation, and discuss your health context with a qualified clinician. The policy is a development worth understanding, not a reason to rush.

Read the full breakdown on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician. Dr. Allen is a Functional Medicine Consultant & Medical Researcher, not a physician. Dr. Sullivan Bryant, DO, is the supervising physician of record.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

WADA's 2027 Prohibited List is out, effective January 1, 2027. Two changes matter for anyone in DFW who competes.Peptide...
11/03/2026

WADA's 2027 Prohibited List is out, effective January 1, 2027. Two changes matter for anyone in DFW who competes.

Peptides are now named explicitly in S0, the non-approved substances category. Unapproved substances can be prohibited even when a specific peptide is not named. GLP-1 medicines like semaglutide and tirzepatide are not prohibited, but they are on WADA's Monitoring Program: tracked, not banned. Prohibited, monitored and not listed are three different things.

BPC-157 remains S0, prohibited at all times. TB-500 remains S2.3 (thymosin beta-4 derivatives), prohibited at all times. In competition and out. An off-season window changes nothing, and a prescription is not an anti-doping exemption.

Strict liability applies regardless of labeling: you can be held responsible for a prohibited substance in your system even if you didn't know it was there. The International Tennis Integrity Agency has already warned players about peptide products promoted through social media.

The irony worth naming: the same month federal policy opened compounding access for some peptides, anti-doping rules tightened. Legal access under one framework does not mean permission to compete under another.

Before anything goes in your body: verify the exact ingredient on GlobalDRO, confirm with your governing body, and talk with a healthcare professional who knows you're tested.

And the recovery-first alternative: physician evaluation, diagnosis, rehabilitation, load management, and for joints, a conversation about whether A*M or PRP is appropriate for you. Boring, evidence-based, and it doesn't risk your eligibility.

Read the full athlete guide on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician. Dr. Allen is a Functional Medicine Consultant & Medical Researcher, not a physician. Dr. Sullivan Bryant, DO, is the supervising physician of record.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

Retatrutide's new NEJM paper proposes a different way to measure obesity care: treating to a target, not just a percenta...
11/02/2026

Retatrutide's new NEJM paper proposes a different way to measure obesity care: treating to a target, not just a percentage.

The trial numbers, stated plainly: at 80 weeks, average weight change was 17.6%, 23.7% and 25.0% across the three retatrutide groups, versus 3.9% for placebo. In the 12 mg group, 65.3% of participants reached a BMI below 30. Among participants who started with class 1 obesity, more than 90% in the 9 mg and 12 mg groups dropped below BMI 30, versus about 20% on placebo. The same paper reported knee osteoarthritis pain improvements and reductions in sleep apnea events.

The honest half: in a separate head-to-head trial announced by the manufacturer, discontinuation due to adverse events was 4.8% at 9 mg and 7.9% at 12 mg, versus 2.7% for semaglutide. Those are topline results from a different population, not peer-reviewed figures from this trial. And BMI is one measure, not a complete health assessment.

What this does not mean: retatrutide remains investigational. It is not FDA-approved, not available by prescription, not included in the federal peptide policy, and not legal to sell to consumers. A planned FDA filing in Q1 2027 is a step in the review process, not an approval. Avoid any "research use" vials sold as retatrutide online.

What you can do today: baseline metabolic labs, body-composition tracking, nutrition and resistance training, and an evidence-based conversation about approved options with a qualified care team.

Read the full analysis on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician. Dr. Allen is a Functional Medicine Consultant & Medical Researcher, not a physician. Dr. Sullivan Bryant, DO, is the supervising physician of record.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

The federal peptide policy opened for comments. As of October 31, the docket showed zero posted comments.Here's what's a...
11/01/2026

The federal peptide policy opened for comments. As of October 31, the docket showed zero posted comments.

Here's what's actually open: HHS-OASH-2026-0496, the interim enforcement-discretion policy published October 30 (91 FR 68526). Comments are accepted through 11:59 PM ET, November 13. Late comments are not accepted.

What the window covers: six peptide bulk substances (BPC-157, TB-500, epitalon, KPV, MOTS-c, semax) under ten conditions, per the policy's own terms as summarized by legal analysts: single active ingredient, valid COA from an FDA-registered CGMP facility, patient-specific prescription, MedWatch adverse-event reporting, 510(k)-cleared syringes only, documented oral bioavailability for oral products.

What it does not decide: whether these peptides join the 503A bulks list. That requires separate FDA rulemaking, which has not begun. The window also doesn't override state pharmacy rules, and HHS reserves the right to revisit the policy if a safety signal appears.

The public record so far is a both-sides ledger: the compounding alliance frames it as harm reduction; PhRMA says it "undermines the FDA's science-based review"; Public Citizen calls it "reckless and unilateral." FDA career scientists raised concerns during the advisory process.

Your perspective can contribute to that record. Read the Federal Register notice first. Check the docket for current counts.

Read the full breakdown on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

Two things happened to Epitalon this month, and they point in different directions.The federal list changed. On October ...
10/31/2026

Two things happened to Epitalon this month, and they point in different directions.

The federal list changed. On October 30, HHS published an interim enforcement-discretion policy covering epitalon (subcutaneous/intramuscular acetate) under ten conditions, including patient-specific prescriptions, FDA-registered CGMP sourcing with a certificate of analysis, and adverse-event reporting. A public comment window is open through November 13 (docket HHS-OASH-2026-0496).

The science did not move. A peer-reviewed review published October 8 walked through 25 years of research and found the telomere findings are cell-culture only. No adequately powered human randomised controlled trial exists. No long-term safety data exists.

One more thing worth knowing: a 2025 study found possible alternative lengthening of telomeres in breast cancer cell lines. That is not proof of harm in people, but it is an unresolved oncologic safety question that deserves a place in every honest conversation.

And the "no side effects" basis behind its listing traces to a Russian-language abstract with no participant numbers or methods.

Here is what the policy is not: it is not FDA approval. Compounded drugs receive no pre-sale FDA check of safety, effectiveness or quality. It does not add epitalon to the 503A bulks list. That requires separate rulemaking, which has not begun.

Being on the list is not being proven.

Read the full analysis on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician. Dr. Allen is a Functional Medicine Consultant & Medical Researcher, not a physician. Dr. Sullivan Bryant, DO, is the supervising physician of record.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

10/29/2026

How much of your day do you spend trying to feel like yourself again?

You reread the same paragraph. Lose your train of thought. Forget why you walked into a room. By evening, you’re exhausted from trying to keep up.

If you’re living with Long COVID, brain fog, attention difficulties, or poor memory, please hear this: "you deserve to be taken seriously—even without a formal ADHD or generalized anxiety disorder diagnosis."

And if you don’t want to take a stimulant such as Adderall, Focalin, or Concerta, say so. Your preferences belong in the conversation.

Here’s my loving challenge: "give yourself permission to seek answers." Tell your clinician what has changed, how it affects your life, and what matters to you. Ask for a thoughtful evaluation and discuss appropriate options, including approaches that do not involve stimulants.

As you watch this comparison, bring curiosity and ask about the evidence. Semax should not be assumed to be a proven substitute for ADHD medication or an established treatment for Long COVID, but definitely something to research and consider.

Your quality of life deserves attention, compassion, and a plan built around you.

—Dr. Allen & Dr. Bryant
BHFS Medical & Wellness

NAD+ is everywhere in longevity conversations right now. Here's the honest version.NAD+ is a molecule your cells use to ...
10/28/2026

NAD+ is everywhere in longevity conversations right now. Here's the honest version.

NAD+ is a molecule your cells use to make energy. It matters. It is also not a shortcut, and the habits around it do most of the work.

WHAT ACTUALLY SUPPORTS IT
• Consistent sleep. The foundation everything else sits on.
• Adequate protein across the day, not in one meal.
• Movement you can sustain. Walking counts.
• Real food and hydration before anything else.

If you are exploring NAD+ therapy, the questions that matter: who is supervising it, what is your baseline, and how will you know if it is doing anything?

Habits first. Everything else is a support.

Read the full guide on the BHFS Medical & Wellness blog: www.bhfsmedical.com

Educational only, not individualised medical advice. Suitability must be determined by a qualified clinician.

BHFS Medical & Wellness | Burleson & DFW
866-943-7779 | www.bhfsmedical.com

Address

212 NE WILSHIRE Boulevard SUITE 206
Burleson, TX
76028

Opening Hours

Monday 10am - 5pm
Tuesday 10am - 5pm
Wednesday 10am - 5pm
Thursday 10am - 5pm
Friday 10am - 5pm

Telephone

+18669437779

Alerts

Be the first to know and let us send you an email when BHFS Medical & Wellness posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Nearby clinics